MedTrace Logo

Pronostic and Predictive Value of EMT in Localized Lung Cancer

NCT03509779 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2018-09-06

No results posted yet for this study

Summary

The goal of the present research is to identify an "EMT signature", associated with long term disease-free survival after surgery in NSCLC. This study will potentially lead to specific treatment recommendations, thanks to an integrated molecular approach including DNA, RNA and miR profiling In vitro analyses using lung cancer cell lines will subsequently be conducted to validate markers identified in tumor screenings.

Conditions

  • NSCLC, Stage I, II, IIIA, IIIB
  • Surgery
  • Progression
  • Epithelial Mesenchymal Transition

Sponsors & Collaborators

  • APHP

    collaborator OTHER

  • European Georges Pompidou Hospital

    lead OTHER

Principal Investigators

  • Francoise Lepimpec Barthes, MD PhD · APHP

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-20
Primary Completion
2018-03-31
Completion
2025-12-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03509779 on ClinicalTrials.gov